nebivolol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
beta-adrenoreceptor antagonists	1887	118457-14-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: nebivolol nebivolol hydrochloride vasoxen bystolic nebivolol HCl	A cardioselective ADRENERGIC BETA-1 RECEPTOR ANTAGONIST (beta-blocker) that functions as a VASODILATOR through the endothelial L-arginine/ NITRIC OXIDE system. It is used to manage HYPERTENSION and chronic HEART FAILURE in elderly patients. Molecular weight: 405.44 Formula: C22H25F2NO4 CLOGP: 3.50 LIPINSKI: 0 HAC: 5 HDO: 3 TPSA: 70.95 ALOGS: -4 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

nebivolol
nebivolol hydrochloride
vasoxen
bystolic
nebivolol HCl

A cardioselective ADRENERGIC BETA-1 RECEPTOR ANTAGONIST (beta-blocker) that functions as a VASODILATOR through the endothelial L-arginine/ NITRIC OXIDE system. It is used to manage HYPERTENSION and chronic HEART FAILURE in elderly patients.

Molecular weight: 405.44
Formula: C22H25F2NO4
CLOGP: 3.50
LIPINSKI: 0
HAC: 5
HDO: 3
TPSA: 70.95
ALOGS: -4
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
5	mg	O

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.35 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	50 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	11 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	14 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.02 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	10 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	0.04 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
Dec. 17, 2007	FDA	FOREST LABS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute kidney injury	226.57	11.61	438	30793	262977	63194814
Bradycardia	194.97	11.61	209	31022	73018	63384773
Hyponatraemia	163.11	11.61	236	30995	111664	63346127
Hypertensive crisis	141.04	11.61	90	31141	15196	63442595
Hypotension	112.05	11.61	341	30890	272263	63185528
Drug interaction	98.23	11.61	291	30940	228840	63228951
Anaemia	91.13	11.61	334	30897	293096	63164695
Systemic lupus erythematosus	89.33	11.61	3	31228	208915	63248876
Joint swelling	79.35	11.61	31	31200	327635	63130156
Synovitis	75.53	11.61	4	31227	186914	63270877
Syncope	74.79	11.61	173	31058	117212	63340579
Treatment failure	72.58	11.61	7	31224	199036	63258755
Fall	68.30	11.61	376	30855	391958	63065833
Arthropathy	68.03	11.61	16	31215	234776	63223015
Glossodynia	65.99	11.61	6	31225	178870	63278921
Maternal exposure during pregnancy	65.76	11.61	14	31217	220048	63237743
Acute motor-sensory axonal neuropathy	59.72	11.61	16	31215	273	63457518
Pain	58.67	11.61	179	31052	740449	62717342
Rhabdomyolysis	55.82	11.61	87	31144	43864	63413927
Rheumatoid arthritis	55.15	11.61	28	31203	253791	63204000
Therapeutic product effect decreased	54.32	11.61	14	31217	193173	63264618
Traumatic coma	52.16	11.61	11	31220	61	63457730
Infusion related reaction	51.99	11.61	28	31203	245493	63212298
Sopor	51.56	11.61	59	31172	22105	63435686
Lip oedema	51.52	11.61	29	31202	3895	63453896
Ischaemic stroke	50.83	11.61	53	31178	17904	63439887
Product prescribing error	49.73	11.61	63	31168	26226	63431565
Dyspnoea	49.36	11.61	519	30712	660794	62796997
Angina pectoris	49.03	11.61	67	31164	30011	63427780
Drug ineffective	47.90	11.61	310	30921	1044455	62413336
Hyperkalaemia	46.22	11.61	90	31141	54113	63403678
Cardiac failure	45.76	11.61	121	31110	89021	63368770
Cholestasis	45.63	11.61	64	31167	29370	63428421
Melaena	45.56	11.61	65	31166	30300	63427491
Contraindicated product administered	44.37	11.61	26	31205	217622	63240169
Atrial fibrillation	44.17	11.61	142	31089	116494	63341297
Hypokalaemia	40.79	11.61	128	31103	103676	63354115
Exposure during pregnancy	40.54	11.61	13	31218	155534	63302257
Swelling	39.91	11.61	46	31185	275332	63182459
Hypomagnesaemia	39.47	11.61	59	31172	28678	63429113
Therapeutic drug monitoring analysis not performed	38.77	11.61	17	31214	1335	63456456
Abdominal discomfort	38.06	11.61	62	31169	320823	63136968
Pericarditis	38.02	11.61	9	31222	131570	63326221
Systemic infection	37.03	11.61	25	31206	4635	63453156
Vertigo	36.73	11.61	87	31144	59800	63397991
General physical health deterioration	34.92	11.61	193	31038	201209	63256582
Cerebellar ataxia	34.77	11.61	14	31217	888	63456903
Hepatocellular injury	34.48	11.61	54	31177	27327	63430464
Arthralgia	34.30	11.61	154	31077	569556	62888235
Wound	31.20	11.61	21	31210	163242	63294549
Primary hyperaldosteronism	30.97	11.61	7	31224	56	63457735
Arrhythmia	30.90	11.61	62	31169	38078	63419713
Drug hypersensitivity	30.70	11.61	67	31164	310620	63147171
Drug intolerance	30.14	11.61	67	31164	308594	63149197
Discomfort	30.06	11.61	23	31208	167351	63290440
Asthenia	29.40	11.61	303	30928	383301	63074490
Product use issue	28.65	11.61	40	31191	220480	63237311
Tongue oedema	28.11	11.61	21	31210	4565	63453226
Miosis	26.96	11.61	25	31206	7328	63450463
Renin decreased	26.91	11.61	7	31224	106	63457685
Sprue-like enteropathy	26.82	11.61	11	31220	732	63457059
Angioedema	26.55	11.61	67	31164	47898	63409893
Erythrosis	26.12	11.61	6	31225	52	63457739
Musculoskeletal stiffness	25.49	11.61	32	31199	184586	63273205
Hypersensitivity	25.06	11.61	68	31163	292617	63165174
Renal failure	24.72	11.61	119	31112	117533	63340258
Electrolyte imbalance	24.46	11.61	39	31192	20037	63437754
Chronic obstructive pulmonary disease	24.34	11.61	77	31154	62609	63395182
Oedema peripheral	24.26	11.61	168	31063	189343	63268448
Retroperitoneal haematoma	24.04	11.61	16	31215	2897	63454894
Metabolic acidosis	23.96	11.61	62	31169	45007	63412784
Infection	22.97	11.61	49	31182	229124	63228667
Blood aldosterone increased	22.85	11.61	7	31224	196	63457595
Walking disability	22.77	11.61	12	31219	1415	63456376
Hypocalcaemia	22.70	11.61	49	31182	31664	63426127
Resting tremor	22.48	11.61	10	31221	813	63456978
Rash	22.32	11.61	173	31058	560698	62897093
Nasopharyngitis	21.81	11.61	59	31172	254198	63203593
Disorientation	21.72	11.61	55	31176	39397	63418394
Mobility decreased	21.30	11.61	17	31214	121142	63336649
Impaired healing	21.23	11.61	12	31219	102530	63355261
Vascular encephalopathy	21.08	11.61	8	31223	433	63457358
Hypoglycaemia	20.82	11.61	71	31160	59994	63397797
Loss of personal independence in daily activities	20.71	11.61	11	31220	97279	63360512
Cerebral haematoma	20.67	11.61	16	31215	3667	63454124
Respiratory failure	20.66	11.61	102	31129	101756	63356035
Labelled drug-drug interaction medication error	20.57	11.61	29	31202	13370	63444421
Fibromyalgia	20.45	11.61	7	31224	80413	63377378
Arterial spasm	20.22	11.61	5	31226	61	63457730
Chronic pigmented purpura	19.83	11.61	6	31225	161	63457630
Alopecia	19.81	11.61	92	31139	337444	63120347
Agranulocytosis	19.34	11.61	40	31191	25094	63432697
Therapeutic drug monitoring analysis incorrectly performed	19.23	11.61	7	31224	337	63457454
Aeromonas infection	19.14	11.61	5	31226	77	63457714
Hypoosmolar state	19.00	11.61	6	31225	186	63457605
Presyncope	18.83	11.61	42	31189	27743	63430048
Peripheral ischaemia	18.69	11.61	17	31214	4861	63452930
Upper respiratory tract irritation	18.23	11.61	6	31225	213	63457578
Hemiparesis	17.85	11.61	37	31194	23245	63434546
Gastrointestinal disorder	17.85	11.61	23	31208	131216	63326575
Adenocarcinoma metastatic	17.78	11.61	5	31226	103	63457688
Drop attacks	17.71	11.61	8	31223	674	63457117
Blood loss anaemia	17.70	11.61	22	31209	8979	63448812
Hyperammonaemia	17.67	11.61	17	31214	5215	63452576
Leukopenia	17.56	11.61	80	31151	77210	63380581
Urine output increased	17.49	11.61	10	31221	1383	63456408
Electrocardiogram abnormal	17.36	11.61	22	31209	9157	63448634
Haematoma	16.59	11.61	46	31185	34774	63423017
Haematoma muscle	16.57	11.61	9	31222	1128	63456663
Elephantiasis	16.56	11.61	3	31228	6	63457785
Hypochloraemia	16.50	11.61	11	31220	1998	63455793
Blister	16.40	11.61	24	31207	129790	63328001
Nocturia	16.17	11.61	20	31211	8121	63449670
Rectal haemorrhage	16.16	11.61	57	31174	48973	63408818
Diarrhoea	16.14	11.61	463	30768	714903	62742888
Cerebral haemorrhage	16.05	11.61	42	31189	30687	63427104
Sinus bradycardia	16.01	11.61	27	31204	14524	63443267
Hypersensitivity pneumonitis	15.94	11.61	12	31219	2638	63455153
Off label use	15.88	11.61	235	30996	674227	62783564
Liver injury	15.86	11.61	5	31226	60515	63397276
Disorganised speech	15.67	11.61	9	31222	1256	63456535
Toxic skin eruption	15.65	11.61	25	31206	12860	63444931
Suicide attempt	15.32	11.61	65	31166	60853	63396938
Diffuse large B-cell lymphoma stage II	15.29	11.61	4	31227	62	63457729
Microcytic anaemia	15.24	11.61	13	31218	3416	63454375
Electrocardiogram Q wave abnormal	15.18	11.61	5	31226	178	63457613
Pancreatitis acute	15.09	11.61	38	31193	27128	63430663
Cerebral salt-wasting syndrome	15.06	11.61	4	31227	66	63457725
Ill-defined disorder	14.97	11.61	11	31220	81744	63376047
Epistaxis	14.86	11.61	73	31158	72652	63385139
Thrombocytopenia	14.85	11.61	126	31105	151031	63306760
Nasal mucosal erosion	14.83	11.61	4	31227	70	63457721
Dry gangrene	14.82	11.61	7	31224	653	63457138
Anuria	14.76	11.61	24	31207	12527	63445264
Wrong schedule	14.74	11.61	5	31226	195	63457596
Neutropenia	14.71	11.61	141	31090	174864	63282927
Pneumonia haemophilus	14.67	11.61	7	31224	668	63457123
Platelet disorder	14.56	11.61	10	31221	1906	63455885
Sinusitis	14.36	11.61	60	31171	226593	63231198
Face oedema	14.20	11.61	31	31200	20181	63437610
Interstitial lung disease	14.00	11.61	64	31167	61844	63395947
Irritable bowel syndrome	13.94	11.61	12	31219	82400	63375391
Cardiac failure acute	13.72	11.61	20	31211	9503	63448288
Intraventricular haemorrhage	13.65	11.61	10	31221	2110	63455681
Orthostatic hypotension	13.65	11.61	44	31187	36116	63421675
Glycosylated haemoglobin increased	13.63	11.61	23	31208	12375	63445416
Renal impairment	13.54	11.61	82	31149	88273	63369518
Hypovolaemic shock	13.49	11.61	16	31215	6225	63451566
Diaphragmatic disorder	13.38	11.61	6	31225	497	63457294
Catheter site injury	13.33	11.61	5	31226	262	63457529
Shock haemorrhagic	13.13	11.61	20	31211	9875	63447916
Blood creatinine increased	13.13	11.61	81	31150	87763	63370028
Sinus rhythm	13.10	11.61	7	31224	849	63456942
Product measured potency issue	13.09	11.61	4	31227	111	63457680
Drug abuse	12.88	11.61	70	31161	72448	63385343
International normalised ratio increased	12.83	11.61	51	31180	46374	63411417
Coronavirus infection	12.78	11.61	13	31218	4265	63453526
Haemorrhagic stroke	12.77	11.61	15	31216	5777	63452014
Intra-abdominal haematoma	12.73	11.61	9	31222	1796	63455995
Renal function test abnormal	12.58	11.61	12	31219	3641	63454150
Ductal adenocarcinoma of pancreas	12.40	11.61	4	31227	133	63457658
Hip arthroplasty	12.37	11.61	4	31227	47642	63410149
Psychotic behaviour	12.37	11.61	6	31225	594	63457197
Jaundice	12.34	11.61	37	31194	29214	63428577
Mucosal hyperaemia	12.33	11.61	3	31228	34	63457757
Peripheral artery stenosis	12.29	11.61	6	31225	602	63457189
Pallor	12.28	11.61	38	31193	30530	63427261
Action tremor	12.20	11.61	5	31226	332	63457459
Withdrawal hypertension	12.10	11.61	4	31227	144	63457647
Arterial thrombosis	12.09	11.61	8	31223	1435	63456356
Stomatitis	12.03	11.61	32	31199	138693	63319098
Hyperuricaemia	11.99	11.61	14	31217	5356	63452435
Dizziness	11.90	11.61	286	30945	429639	63028152
Pyramidal tract syndrome	11.84	11.61	5	31226	358	63457433
Dedifferentiated liposarcoma	11.68	11.61	3	31228	43	63457748

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute kidney injury	159.39	12.05	547	25770	304441	34626173
Hyperkalaemia	133.49	12.05	209	26108	69180	34861434
Lactic acidosis	95.23	12.05	124	26193	34648	34895966
Bradycardia	82.45	12.05	178	26139	75240	34855374
Hypoparathyroidism	71.61	12.05	24	26293	581	34930033
Hypertensive crisis	64.14	12.05	53	26264	8698	34921916
Hypokalaemia	57.51	12.05	132	26185	58082	34872532
Syncope	51.80	12.05	169	26148	91282	34839332
Toxicity to various agents	50.42	12.05	46	26271	200316	34730298
Hypotension	45.58	12.05	304	26013	221345	34709269
Death	42.22	12.05	156	26161	397893	34532721
Hypomagnesaemia	36.75	12.05	62	26255	21789	34908825
Drug interaction	36.72	12.05	293	26024	225653	34704961
Akinesia	36.72	12.05	22	26295	2162	34928452
Cerebral haematoma	36.02	12.05	29	26288	4586	34926028
Renal artery thrombosis	31.45	12.05	11	26306	304	34930310
Hypocalcaemia	30.81	12.05	61	26256	24228	34906386
Shock haemorrhagic	30.30	12.05	40	26277	11314	34919300
Burnout syndrome	30.11	12.05	9	26308	148	34930466
Labelled drug-drug interaction medication error	30.06	12.05	46	26271	14893	34915721
Presyncope	29.33	12.05	52	26265	19007	34911607
Melaena	29.32	12.05	75	26242	35305	34895309
Product monitoring error	28.95	12.05	25	26292	4356	34926258
Cardiac failure	28.47	12.05	140	26177	91108	34839506
Anaemia	28.32	12.05	284	26033	233051	34697563
Cardiac failure chronic	27.88	12.05	32	26285	7847	34922767
Vascular purpura	27.55	12.05	17	26300	1761	34928853
Cerebellar ischaemia	27.15	12.05	8	26309	125	34930489
Ischaemic stroke	27.07	12.05	49	26268	18201	34912413
Blood lactic acid	26.74	12.05	10	26307	336	34930278
Interstitial lung disease	26.24	12.05	108	26209	65174	34865440
Renal failure	26.12	12.05	178	26139	130379	34800235
Fungal endocarditis	25.83	12.05	10	26307	370	34930244
Extrasystoles	25.63	12.05	22	26295	3801	34926813
Pemphigoid	25.42	12.05	32	26285	8634	34921980
Febrile neutropenia	25.26	12.05	40	26277	136809	34793805
White blood cell count decreased	25.07	12.05	21	26296	95424	34835190
Cutaneous lupus erythematosus	24.94	12.05	12	26305	758	34929856
Intercapillary glomerulosclerosis	24.84	12.05	6	26311	41	34930573
Coma uraemic	24.84	12.05	6	26311	41	34930573
Vitamin B12 decreased	24.50	12.05	14	26303	1259	34929355
Lung diffusion test abnormal	23.69	12.05	6	26311	51	34930563
Left ventricular false tendon	23.38	12.05	6	26311	54	34930560
Drug reaction with eosinophilia and systemic symptoms	23.35	12.05	66	26251	32946	34897668
Cerebellar syndrome	23.00	12.05	17	26300	2371	34928243
Laryngeal cancer metastatic	22.90	12.05	6	26311	59	34930555
Brief psychotic disorder with marked stressors	22.81	12.05	8	26309	223	34930391
Inferior vena cava syndrome	22.64	12.05	6	26311	62	34930552
Decreased ventricular preload	22.55	12.05	5	26312	22	34930592
Angina pectoris	22.47	12.05	63	26254	31300	34899314
Drug abuse	22.32	12.05	25	26292	99071	34831543
Renal ischaemia	21.93	12.05	10	26307	559	34930055
Blood cholinesterase decreased	21.87	12.05	7	26310	146	34930468
Cholestasis	21.17	12.05	56	26261	26892	34903722
Vertigo	21.02	12.05	54	26263	25482	34905132
Hepatic function abnormal	20.93	12.05	4	26313	44359	34886255
Electrocardiogram abnormal	20.80	12.05	30	26287	9217	34921397
Potentiating drug interaction	20.70	12.05	22	26295	4955	34925659
Hepatocellular injury	20.42	12.05	49	26268	22162	34908452
Neutrophil count decreased	19.56	12.05	7	26310	51097	34879517
Myalgia	19.46	12.05	119	26198	83991	34846623
Anticoagulation drug level increased	19.28	12.05	9	26308	531	34930083
Bundle branch block left	19.02	12.05	23	26294	5956	34924658
Bronchitis bacterial	19.00	12.05	10	26307	765	34929849
Agoraphobia	18.45	12.05	7	26310	245	34930369
Enzyme induction	18.42	12.05	5	26312	57	34930557
Acute coronary syndrome	18.37	12.05	35	26282	13510	34917104
Platelet count decreased	17.68	12.05	40	26277	119677	34810937
Carbohydrate metabolism disorder	17.62	12.05	4	26313	20	34930594
Neurosis	17.46	12.05	6	26311	157	34930457
Infective exacerbation of chronic obstructive airways disease	17.43	12.05	13	26304	1838	34928776
Eosinophilia	17.17	12.05	51	26266	26171	34904443
Left ventricle outflow tract obstruction	17.11	12.05	6	26311	167	34930447
Hypertensive nephropathy	16.97	12.05	8	26309	483	34930131
Retinal disorder	16.84	12.05	10	26307	967	34929647
Dialysis device insertion	16.60	12.05	4	26313	27	34930587
Congestive cardiomyopathy	16.36	12.05	24	26293	7486	34923128
Ventricular internal diameter abnormal	16.18	12.05	6	26311	197	34930417
Infusion related reaction	16.11	12.05	10	26307	53047	34877567
Haematoma	16.01	12.05	49	26268	25556	34905058
Diabetic nephropathy	15.82	12.05	13	26304	2115	34928499
Orthostatic intolerance	15.70	12.05	9	26308	814	34929800
Orthostatic hypotension	15.65	12.05	49	26268	25870	34904744
Metabolic alkalosis	15.16	12.05	11	26306	1490	34929124
Atrioventricular block	15.07	12.05	24	26293	8039	34922575
Metabolic acidosis	15.05	12.05	69	26248	43611	34887003
Blood creatine phosphokinase MB increased	15.03	12.05	12	26305	1874	34928740
Haemorrhagic transformation stroke	15.02	12.05	11	26306	1512	34929102
Hyponatraemia	14.92	12.05	110	26207	82581	34848033
Normocytic anaemia	14.73	12.05	13	26304	2331	34928283
Electrocardiogram T wave abnormal	14.53	12.05	11	26306	1590	34929024
Perioral dermatitis	14.13	12.05	5	26312	143	34930471
Dyspnoea	14.07	12.05	377	25940	376405	34554209
Funguria	13.98	12.05	4	26313	56	34930558
Traumatic haemothorax	13.87	12.05	6	26311	296	34930318
Sinus arrest	13.72	12.05	11	26306	1729	34928885
Carcinogenicity	13.66	12.05	4	26313	61	34930553
Jealous delusion	13.66	12.05	6	26311	307	34930307
Alanine aminotransferase increased	13.63	12.05	25	26292	80790	34849824
Coma	13.46	12.05	69	26248	45609	34885005
Dermatosis	13.39	12.05	6	26311	322	34930292
Haemoglobinaemia	13.26	12.05	5	26312	172	34930442
N-terminal prohormone brain natriuretic peptide increased	13.10	12.05	13	26304	2702	34927912
Congenital inguinal hernia	13.07	12.05	5	26312	179	34930435
Anuria	13.07	12.05	26	26291	10359	34920255
Transient ischaemic attack	12.97	12.05	48	26269	27565	34903049
Cardioactive drug level decreased	12.84	12.05	4	26313	76	34930538
Oral lichen planus	12.84	12.05	5	26312	188	34930426
Electrocardiogram T wave amplitude decreased	12.82	12.05	6	26311	356	34930258
Hyperventilation	12.67	12.05	13	26304	2811	34927803
Gingival discomfort	12.65	12.05	4	26313	80	34930534
Systemic scleroderma	12.65	12.05	6	26311	367	34930247
Acute pulmonary oedema	12.56	12.05	21	26296	7322	34923292
Albumin urine present	12.49	12.05	6	26311	378	34930236
Central obesity	12.48	12.05	7	26310	608	34930006
Hypoglycaemia	12.43	12.05	77	26240	54563	34876051
Epilepsy	12.39	12.05	40	26277	21455	34909159
Ejection fraction decreased	12.30	12.05	37	26280	19117	34911497
Electrocardiogram QT prolonged	12.16	12.05	62	26255	40890	34889724
Malpositioned teeth	12.12	12.05	3	26314	23	34930591
Haemorrhagic erosive gastritis	12.12	12.05	5	26312	219	34930395

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute kidney injury	390.42	10.60	946	49207	518458	79175777
Bradycardia	231.68	10.60	351	49802	135206	79559029
Hypertensive crisis	202.92	10.60	139	50014	20631	79673604
Hyperkalaemia	170.14	10.60	278	49875	114120	79580115
Hyponatraemia	139.36	10.60	330	49823	177518	79516717
Hypotension	138.01	10.60	595	49558	439722	79254513
Drug interaction	129.28	10.60	560	49593	414623	79279612
Syncope	123.66	10.60	317	49836	179132	79515103
Anaemia	114.72	10.60	568	49585	444447	79249788
Lactic acidosis	90.03	10.60	160	49993	70199	79624036
Hypokalaemia	78.86	10.60	234	49919	143806	79550429
Synovitis	78.22	10.60	4	50149	150730	79543505
Melaena	74.75	10.60	136	50017	60754	79633481
Ischaemic stroke	71.55	10.60	96	50057	33035	79661200
Joint swelling	68.54	10.60	49	50104	288597	79405638
Hypomagnesaemia	66.98	10.60	112	50041	46799	79647436
Cholestasis	64.74	10.60	117	50036	51992	79642243
Cardiac failure	63.51	10.60	228	49925	154614	79539621
Pain	62.52	10.60	230	49923	703572	78990663
Infusion related reaction	61.66	10.60	34	50119	230203	79464032
Systemic lupus erythematosus	60.46	10.60	4	50149	121145	79573090
Arthropathy	58.87	10.60	19	50134	177092	79517143
Vertigo	58.21	10.60	132	50021	68950	79625285
Fall	57.51	10.60	512	49641	487117	79207118
Therapeutic product effect decreased	57.33	10.60	16	50137	163847	79530388
Treatment failure	57.18	10.60	18	50135	170468	79523767
Maternal exposure during pregnancy	56.63	10.60	9	50144	136529	79557706
Rheumatoid arthritis	55.51	10.60	31	50122	208439	79485796
Angina pectoris	55.38	10.60	109	50044	51623	79642612
Cerebral haematoma	54.58	10.60	43	50110	7899	79686336
Hepatocellular injury	53.04	10.60	102	50051	47491	79646744
Hypocalcaemia	52.01	10.60	104	50049	49820	79644415
Acute motor-sensory axonal neuropathy	49.59	10.60	16	50137	413	79693822
Labelled drug-drug interaction medication error	49.15	10.60	73	50080	27577	79666658
Dyspnoea	48.61	10.60	782	49371	856243	78837992
Drug hypersensitivity	47.03	10.60	72	50081	298844	79395391
Presyncope	47.00	10.60	89	50064	40965	79653270
Sopor	46.04	10.60	78	50075	32932	79661303
Exposure during pregnancy	45.92	10.60	5	50148	101127	79593108
Traumatic coma	45.84	10.60	10	50143	50	79694185
Hypoparathyroidism	44.67	10.60	19	50134	1079	79693156
Arthralgia	44.32	10.60	197	49956	571606	79122629
Interstitial lung disease	43.79	10.60	163	49990	112437	79581798
Renal failure	43.69	10.60	245	49908	200723	79493512
Shock haemorrhagic	43.11	10.60	58	50095	20002	79674233
Pemphigus	42.59	10.60	6	50147	99576	79594659
General physical health deterioration	42.18	10.60	307	49846	274931	79419304
Toxicity to various agents	41.95	10.60	131	50022	421409	79272826
Atrial fibrillation	41.54	10.60	239	49914	197647	79496588
Lip oedema	40.85	10.60	33	50120	6283	79687952
Metabolic acidosis	40.41	10.60	129	50024	82400	79611835
Electrocardiogram abnormal	40.02	10.60	51	50102	16686	79677549
Drug ineffective	39.07	10.60	464	49689	1080449	78613786
Glossodynia	38.23	10.60	9	50144	103328	79590907
Drug reaction with eosinophilia and systemic symptoms	36.68	10.60	106	50047	64138	79630097
Nasopharyngitis	36.34	10.60	65	50088	253816	79440419
Musculoskeletal stiffness	36.18	10.60	34	50119	174974	79519261
Product prescribing error	35.95	10.60	84	50069	44729	79649506
Extrasystoles	34.29	10.60	32	50121	7387	79686848
Pericarditis	33.21	10.60	12	50141	104224	79590011
Hypoglycaemia	32.99	10.60	139	50014	101455	79592780
Asthenia	30.82	10.60	472	49681	511217	79183018
Haematoma	30.65	10.60	87	50066	52108	79642127
Helicobacter infection	30.28	10.60	4	50149	69700	79624535
Retro-orbital neoplasm	30.08	10.60	7	50146	49	79694186
Cardiac failure chronic	29.95	10.60	36	50117	11099	79683136
Hepatic function abnormal	29.90	10.60	5	50148	73102	79621133
Anuria	29.85	10.60	50	50103	20913	79673322
Fibromyalgia	29.67	10.60	3	50150	64337	79629898
Rhabdomyolysis	29.61	10.60	136	50017	102995	79591240
Acute coronary syndrome	29.55	10.60	50	50103	21083	79673152
Product monitoring error	29.38	10.60	32	50121	8874	79685361
Loss of personal independence in daily activities	29.15	10.60	14	50139	102566	79591669
Therapeutic drug monitoring analysis not performed	29.04	10.60	17	50136	1919	79692316
Eosinophilia	29.02	10.60	78	50075	45267	79648968
Renal artery thrombosis	28.44	10.60	11	50142	488	79693747
Chronic obstructive pulmonary disease	27.83	10.60	117	50036	85302	79608933
Abdominal discomfort	27.77	10.60	74	50079	250653	79443582
Orthostatic hypotension	27.68	10.60	88	50065	56076	79638159
Sinusitis	27.13	10.60	51	50102	195450	79498785
White blood cell count decreased	27.12	10.60	48	50105	188240	79505995
Haemorrhagic stroke	26.95	10.60	34	50119	11012	79683223
Contraindicated product administered	26.67	10.60	36	50117	157502	79536733
Cerebellar ataxia	26.55	10.60	16	50137	1905	79692330
Agranulocytosis	26.39	10.60	75	50078	44955	79649280
Potentiating drug interaction	26.19	10.60	30	50123	8789	79685446
Coma uraemic	25.78	10.60	6	50147	42	79694193
Infective exacerbation of chronic obstructive airways disease	25.70	10.60	18	50135	2766	79691469
Blood lactic acid	25.66	10.60	10	50143	453	79693782
Death	25.35	10.60	231	49922	566283	79127952
Pemphigoid	25.18	10.60	39	50114	15276	79678959
Left ventricular false tendon	25.08	10.60	6	50147	48	79694187
Mobility decreased	24.94	10.60	24	50129	122151	79572084
Electrolyte imbalance	24.89	10.60	58	50095	30823	79663412
Atrioventricular block	24.85	10.60	37	50116	14004	79680231
Cerebral haemorrhage	24.54	10.60	86	50067	57587	79636648
Renin decreased	24.45	10.60	7	50146	119	79694116
Cerebellar ischaemia	23.98	10.60	8	50145	230	79694005
Vascular purpura	23.97	10.60	18	50135	3080	79691155
Sprue-like enteropathy	23.61	10.60	13	50140	1305	79692930
Neutrophil count decreased	23.55	10.60	15	50138	93944	79600291
Intercapillary glomerulosclerosis	23.37	10.60	6	50147	66	79694169
Acute pulmonary oedema	23.07	10.60	36	50117	14194	79680041
Hypersensitivity	22.99	10.60	86	50067	262153	79432082
Primary hyperaldosteronism	22.97	10.60	7	50146	149	79694086
N-terminal prohormone brain natriuretic peptide increased	22.92	10.60	21	50132	4734	79689501
Akinesia	22.90	10.60	18	50135	3294	79690941
Pancreatitis acute	22.89	10.60	76	50077	49528	79644707
Myalgia	22.88	10.60	197	49956	185444	79508791
Epistaxis	22.29	10.60	133	50020	111382	79582853
Systemic infection	22.19	10.60	29	50124	9723	79684512
Folliculitis	22.18	10.60	4	50149	55376	79638859
Sinus bradycardia	22.11	10.60	49	50104	25198	79669037
Carbohydrate metabolism disorder	22.01	10.60	5	50148	31	79694204
Discomfort	21.99	10.60	28	50125	125589	79568646
Brief psychotic disorder with marked stressors	21.94	10.60	8	50145	301	79693934
Product use issue	21.70	10.60	64	50089	209758	79484477
Angioedema	21.62	10.60	100	50053	75935	79618300
Arrhythmia	21.60	10.60	86	50067	61186	79633049
Burnout syndrome	21.28	10.60	8	50145	328	79693907
Decreased ventricular preload	21.13	10.60	5	50148	38	79694197
Inferior vena cava syndrome	21.01	10.60	6	50147	101	79694134
Retroperitoneal haematoma	21.00	10.60	21	50132	5276	79688959
Blood loss anaemia	20.79	10.60	36	50117	15462	79678773
Muscle injury	20.59	10.60	3	50150	48558	79645677
Cerebellar syndrome	20.40	10.60	21	50132	5459	79688776
Blood aldosterone increased	20.36	10.60	7	50146	221	79694014
Oedema peripheral	20.18	10.60	245	49908	252043	79442192
Walking disability	20.12	10.60	14	50139	2129	79692106
Irritable bowel syndrome	20.11	10.60	7	50146	62234	79632001
Cutaneous lupus erythematosus	20.08	10.60	16	50137	2987	79691248
Hyperlactacidaemia	20.04	10.60	21	50132	5574	79688661
Laryngeal cancer metastatic	19.90	10.60	5	50148	50	79694185
Sinus rhythm	19.74	10.60	10	50143	848	79693387
Fungal endocarditis	19.73	10.60	9	50144	605	79693630
Swelling	19.70	10.60	70	50083	216641	79477594
Alopecia	19.55	10.60	77	50076	231278	79462957
Lower respiratory tract infection	19.47	10.60	32	50121	129188	79565047
Sinus arrest	19.45	10.60	17	50136	3605	79690630
Bronchitis bacterial	19.45	10.60	12	50141	1490	79692745
Blood cholinesterase decreased	18.93	10.60	7	50146	274	79693961
Jaundice	18.90	10.60	75	50078	53274	79640961
Stomatitis	18.88	10.60	40	50113	146717	79547518
Febrile neutropenia	18.81	10.60	78	50075	230921	79463314
Drug intolerance	18.64	10.60	94	50059	264025	79430210
Bundle branch block left	18.49	10.60	29	50124	11484	79682751
Erythrosis	18.48	10.60	6	50147	158	79694077
Rash	18.29	10.60	255	49898	578103	79116132
Diabetic nephropathy	18.22	10.60	15	50138	2932	79691303
Renal impairment	18.17	10.60	165	49988	157618	79536617
Infection	17.65	10.60	85	50068	241627	79452608
Arterial thrombosis	17.35	10.60	14	50139	2660	79691575
Wound	17.29	10.60	29	50124	116150	79578085
Haemorrhagic transformation stroke	17.27	10.60	14	50139	2678	79691557
Urinary retention	17.24	10.60	76	50077	56554	79637681
Ill-defined disorder	17.23	10.60	10	50143	65865	79628370
Impaired healing	17.00	10.60	18	50135	87637	79606598
Platelet count decreased	16.95	10.60	64	50089	194600	79499635
Renal ischaemia	16.89	10.60	10	50143	1152	79693083
Arthritis	16.80	10.60	29	50124	114851	79579384
Intentional product use issue	16.75	10.60	45	50108	152067	79542168
Vascular encephalopathy	16.52	10.60	8	50145	615	79693620
Dermatitis bullous	16.45	10.60	31	50122	14214	79680021
Drug dependence	16.21	10.60	3	50150	40766	79653469
Chronic pigmented purpura	16.20	10.60	6	50147	236	79693999
Enzyme induction	16.00	10.60	5	50148	116	79694119
Ventricular internal diameter abnormal	15.96	10.60	6	50147	246	79693989
Blister	15.84	10.60	32	50121	119444	79574791
Stress	15.83	10.60	16	50137	79596	79614639
Blood creatinine increased	15.80	10.60	158	49995	154899	79539336
Upper respiratory tract irritation	15.71	10.60	6	50147	257	79693978
Face oedema	15.65	10.60	46	50107	28090	79666145
Contraindicated product prescribed	15.59	10.60	11	50142	1710	79692525
Muscle mass	15.54	10.60	7	50146	457	79693778
Kidney transplant rejection	15.34	10.60	25	50128	10221	79684014
Loss of consciousness	15.17	10.60	167	49986	167776	79526459
Haemoglobinaemia	15.06	10.60	6	50147	288	79693947
Urine output increased	15.04	10.60	12	50141	2244	79691991
Intracranial mass	15.03	10.60	12	50141	2247	79691988
Elephantiasis	14.96	10.60	3	50150	9	79694226
Anticoagulation drug level increased	14.91	10.60	8	50145	763	79693472
Osteoarthritis	14.72	10.60	20	50133	87289	79606946
Supraventricular extrasystoles	14.71	10.60	20	50133	6967	79687268
Arterial spasm	14.51	10.60	5	50148	159	79694076
Resting tremor	14.43	10.60	10	50143	1511	79692724
Tongue oedema	14.42	10.60	20	50133	7097	79687138
Jealous delusion	14.39	10.60	6	50147	324	79693911
Body temperature increased	14.34	10.60	5	50148	44415	79649820
Dialysis device insertion	14.26	10.60	4	50149	63	79694172
Hepatic mass	14.17	10.60	12	50141	2439	79691796
Hypoosmolar state	14.10	10.60	6	50147	341	79693894
Vitamin B12 decreased	14.09	10.60	14	50139	3491	79690744
Congestive cardiomyopathy	14.05	10.60	26	50127	11754	79682481
Psoriatic arthropathy	14.05	10.60	17	50136	77982	79616253
Rash maculo-papular	13.96	10.60	71	50082	56007	79638228
Hypochloraemia	13.90	10.60	12	50141	2503	79691732
Nasal mucosal erosion	13.86	10.60	4	50149	70	79694165
Blood pressure systolic increased	13.85	10.60	13	50140	66973	79627262
Dermatosis	13.78	10.60	7	50146	597	79693638
Adenocarcinoma metastatic	13.76	10.60	5	50148	186	79694049
Off label use	13.65	10.60	451	49702	906764	78787471
Hypotonia	13.62	10.60	27	50126	12843	79681392
Coronavirus infection	13.62	10.60	20	50133	7477	79686758
Adverse drug reaction	13.59	10.60	13	50140	66379	79627856
Acute myocardial infarction	13.59	10.60	89	50064	76947	79617288
Haematoma muscle	13.49	10.60	12	50141	2603	79691632
Lung diffusion test abnormal	13.43	10.60	6	50147	384	79693851
Mitral valve incompetence	13.39	10.60	44	50109	28521	79665714
Product measured potency issue	13.37	10.60	5	50148	202	79694033
Carcinogenicity	13.22	10.60	4	50149	83	79694152
Language disorder	13.22	10.60	13	50140	3201	79691034
Condition aggravated	13.10	10.60	229	49924	500895	79193340
Polyuria	12.99	10.60	29	50124	14985	79679250
Toxic skin eruption	12.93	10.60	37	50116	22256	79671979
Palpitations	12.89	10.60	129	50024	126481	79567754
Hypertensive nephropathy	12.87	10.60	8	50145	1006	79693229
Blood creatine phosphokinase MB increased	12.75	10.60	12	50141	2799	79691436
Therapeutic drug monitoring analysis incorrectly performed	12.66	10.60	7	50146	709	79693526
Palatal oedema	12.62	10.60	9	50144	1422	79692813
Drop attacks	12.58	10.60	8	50145	1047	79693188
Alanine aminotransferase increased	12.55	10.60	56	50097	162514	79531721
Diarrhoea	12.55	10.60	675	49478	879814	78814421
Diffuse large B-cell lymphoma stage II	12.44	10.60	4	50149	102	79694133
Thrombocytopenia	12.39	10.60	235	49918	265024	79429211
Brain natriuretic peptide increased	12.37	10.60	21	50132	8879	79685356
Orthostatic intolerance	12.33	10.60	10	50143	1914	79692321
Erectile dysfunction	12.32	10.60	28	50125	14636	79679599
Myelosuppression	12.23	10.60	5	50148	40291	79653944
Catheter site injury	12.19	10.60	5	50148	259	79693976
Glycosylated haemoglobin increased	12.19	10.60	33	50120	19227	79675008
Sedation	12.05	10.60	9	50144	51886	79642349
Therapeutic product effect incomplete	12.05	10.60	47	50106	141598	79552637
Dedifferentiated liposarcoma	12.03	10.60	3	50150	29	79694206
Asthma	12.03	10.60	44	50109	135051	79559184
IIIrd nerve disorder	11.99	10.60	4	50149	115	79694120
Red blood cell sedimentation rate increased	11.98	10.60	7	50146	45935	79648300
Hypertensive heart disease	11.98	10.60	14	50139	4192	79690043
Coronary artery stenosis	11.81	10.60	25	50128	12459	79681776
Erysipelas	11.77	10.60	23	50130	10827	79683408
C-reactive protein abnormal	11.74	10.60	8	50145	48359	79645876
Bundle branch block	11.73	10.60	9	50144	1591	79692644
Hydrocholecystis	11.64	10.60	6	50147	527	79693708
Bursitis	11.63	10.60	4	50149	35840	79658395
Renal function test abnormal	11.59	10.60	15	50138	4983	79689252
Anaphylactic shock	11.48	10.60	49	50104	35947	79658288
Cerebral salt-wasting syndrome	11.47	10.60	4	50149	132	79694103
Traumatic haemothorax	11.43	10.60	6	50147	548	79693687
Transient ischaemic attack	11.27	10.60	64	50089	52631	79641604
Agoraphobia	11.19	10.60	6	50147	572	79693663
Weight increased	11.15	10.60	116	50037	277270	79416965
Exophthalmos	11.10	10.60	9	50144	1721	79692514
Malpositioned teeth	11.09	10.60	3	50150	41	79694194
Microcytic anaemia	10.95	10.60	15	50138	5259	79688976
Osteonecrosis of jaw	10.95	10.60	55	50098	43171	79651064
Hypoaesthesia	10.92	10.60	67	50086	179285	79514950
Tonic clonic movements	10.92	10.60	10	50143	2254	79691981
Exercise tolerance decreased	10.80	10.60	20	50133	9051	79685184
Hallucination, visual	10.79	10.60	45	50108	32684	79661551
Faecaloma	10.76	10.60	23	50130	11541	79682694
Ventricular extrasystoles	10.75	10.60	32	50121	19672	79674563
Ductal adenocarcinoma of pancreas	10.74	10.60	4	50149	160	79694075
Disease progression	10.64	10.60	70	50083	184292	79509943
Mental status changes	10.64	10.60	16	50137	66943	79627292
Intra-abdominal haematoma	10.62	10.60	11	50142	2880	79691355

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C07AB12	CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS Beta blocking agents, selective
ATC	C07BB12	CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS AND THIAZIDES Beta blocking agents, selective, and thiazides
ATC	C07FB12	CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS, OTHER COMBINATIONS Beta blocking agents and calcium channel blockers
ATC	C09DX05	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS Angiotensin II receptor blockers (ARBs), other combinations
FDA MoA	N0000000161	Adrenergic beta-Antagonists
FDA EPC	N0000175556	beta-Adrenergic Blocker
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D000322	Adrenergic Agonists
MeSH PA	D058665	Adrenergic beta-1 Receptor Agonists
MeSH PA	D000318	Adrenergic beta-Agonists
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014665	Vasodilator Agents
CHEBI has role	CHEBI:35530	beta-adrenergic blockers
CHEBI has role	CHEBI:35620	vasodilator agents
CHEBI has role	CHEBI:35674	antihypertensive drugs
CHEBI has role	CHEBI:176497	geroprotectors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Chronic heart failure	off-label use	48447003
Atrial fibrillation	off-label use	49436004	DOID:0060224
Angina pectoris	off-label use	194828000
Myocardial Reinfarction Prevention	off-label use
Bronchospasm	contraindication	4386001
Complete atrioventricular block	contraindication	27885002
Sick sinus syndrome	contraindication	36083008	DOID:13884
Bradycardia	contraindication	48867003
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Diabetes mellitus	contraindication	73211009	DOID:9351
Cardiogenic shock	contraindication	89138009
Second degree atrioventricular block	contraindication	195042002
Decompensated cardiac failure	contraindication	195111005
Disease of liver	contraindication	235856003	DOID:409
Hypoglycemic disorder	contraindication	237630007
Peripheral vascular disease	contraindication	400047006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.87	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 5MG BASE;80MG	BYVALSON	ABBVIE	N206302	June 3, 2016	DISCN	TABLET	ORAL	7838552	Oct. 4, 2027	METHOD OF TREATING HYPERTENSION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN	ANTAGONIST	Ki	8.50	WOMBAT-PK	CHEMBL
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN	ANTAGONIST	Ki	7.50	WOMBAT-PK	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	8	WOMBAT-PK
Beta-3 adrenergic receptor	GPCR	P13945	ADRB3_HUMAN	ANTAGONIST	Ki	5.66	IUPHAR

External reference:

ID	Source
4027169	VUID
N0000179202	NUI
D05127	KEGG_DRUG
152520-56-4	SECONDARY_CAS_RN
4027169	VANDF
C0068475	UMLSCUI
CHEBI:64022	CHEBI
CHEMBL434394	ChEMBL_ID
CHEMBL1201731	ChEMBL_ID
D000068577	MESH_DESCRIPTOR_UI
DB04861	DRUGBANK_ID
71301	PUBCHEM_CID
7246	IUPHAR_LIGAND_ID
5969	INN_ID
030Y90569U	UNII
236883	RXNORM
130026	MMSL
18486	MMSL
29969	MMSL
52690	MMSL
d05265	MMSL
007077	NDDF
007078	NDDF
318638009	SNOMEDCT_US
395808005	SNOMEDCT_US
734565001	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Bystolic	HUMAN PRESCRIPTION DRUG LABEL	1	0456-1402	TABLET	2.50 mg	ORAL	NDA	27 sections
Bystolic	HUMAN PRESCRIPTION DRUG LABEL	1	0456-1402	TABLET	2.50 mg	ORAL	NDA	27 sections
Bystolic	HUMAN PRESCRIPTION DRUG LABEL	1	0456-1402	TABLET	2.50 mg	ORAL	NDA	27 sections
Bystolic	HUMAN PRESCRIPTION DRUG LABEL	1	0456-1405	TABLET	5 mg	ORAL	NDA	27 sections
Bystolic	HUMAN PRESCRIPTION DRUG LABEL	1	0456-1405	TABLET	5 mg	ORAL	NDA	27 sections
Bystolic	HUMAN PRESCRIPTION DRUG LABEL	1	0456-1405	TABLET	5 mg	ORAL	NDA	27 sections
Bystolic	HUMAN PRESCRIPTION DRUG LABEL	1	0456-1410	TABLET	10 mg	ORAL	NDA	27 sections
Bystolic	HUMAN PRESCRIPTION DRUG LABEL	1	0456-1410	TABLET	10 mg	ORAL	NDA	27 sections
Bystolic	HUMAN PRESCRIPTION DRUG LABEL	1	0456-1410	TABLET	10 mg	ORAL	NDA	27 sections
Bystolic	HUMAN PRESCRIPTION DRUG LABEL	1	0456-1420	TABLET	20 mg	ORAL	NDA	27 sections
Bystolic	HUMAN PRESCRIPTION DRUG LABEL	1	0456-1420	TABLET	20 mg	ORAL	NDA	27 sections
Bystolic	HUMAN PRESCRIPTION DRUG LABEL	1	0456-1420	TABLET	20 mg	ORAL	NDA	27 sections
nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7189	TABLET	5 mg	ORAL	ANDA	25 sections
nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7189	TABLET	5 mg	ORAL	ANDA	25 sections
nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7190	TABLET	10 mg	ORAL	ANDA	25 sections
nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7190	TABLET	10 mg	ORAL	ANDA	25 sections
nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7225	TABLET	2.50 mg	ORAL	ANDA	25 sections
nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7225	TABLET	2.50 mg	ORAL	ANDA	25 sections
nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7226	TABLET	20 mg	ORAL	ANDA	25 sections
nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7226	TABLET	20 mg	ORAL	ANDA	25 sections
nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	13668-353	TABLET	2.50 mg	ORAL	ANDA	26 sections
nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	13668-353	TABLET	2.50 mg	ORAL	ANDA	26 sections
nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	13668-353	TABLET	2.50 mg	ORAL	ANDA	26 sections
nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	13668-353	TABLET	2.50 mg	ORAL	ANDA	26 sections
nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	13668-354	TABLET	5 mg	ORAL	ANDA	26 sections
nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	13668-354	TABLET	5 mg	ORAL	ANDA	26 sections
nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	13668-354	TABLET	5 mg	ORAL	ANDA	26 sections
nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	13668-354	TABLET	5 mg	ORAL	ANDA	26 sections
nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	13668-355	TABLET	10 mg	ORAL	ANDA	26 sections
nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	13668-355	TABLET	10 mg	ORAL	ANDA	26 sections